GT200200085A - Derivados de oxazol - Google Patents

Derivados de oxazol

Info

Publication number
GT200200085A
GT200200085A GT200200085A GT200200085A GT200200085A GT 200200085 A GT200200085 A GT 200200085A GT 200200085 A GT200200085 A GT 200200085A GT 200200085 A GT200200085 A GT 200200085A GT 200200085 A GT200200085 A GT 200200085A
Authority
GT
Guatemala
Prior art keywords
ppar
effect
oxazol
derivatives
oxazol derivatives
Prior art date
Application number
GT200200085A
Other languages
English (en)
Inventor
Alfred Binggeli
Markus Boehringer
Uwe Grether
Hans Hilpert
Han-Peter Maerki
Markus Meyer
Peter Mohr
Fabienne Riclin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200200085A publication Critical patent/GT200200085A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A DERIVADOS DE OXAZOL DE FORMULA GENERAL (I) EN DONDE R1,R2,R3,R4,R5, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ADEMAS HACE MENCION A SU ELABORACION Y A SU USO COMO MEDICAMENTOS. ESTOS COMPUESTOS SON UTILES EN CASOS DE DIABETES, ENTRE OTRAS, DEBIDO A QUE SE UNEN Y ACTIVAN A LOS PPAR ALFA Y PPAR GAMMA POR LO QUE VAN A COMBINAR EL EFECTO ANTIGLICEMICO DE LOS PPAR GAMMA CON EL EFECTO ANTIDISLIPIDEMICO DE LOS PPAR ALFA.
GT200200085A 2001-05-15 2002-05-14 Derivados de oxazol GT200200085A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01111745 2001-05-15

Publications (1)

Publication Number Publication Date
GT200200085A true GT200200085A (es) 2003-01-16

Family

ID=8177436

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200200085A GT200200085A (es) 2001-05-15 2002-05-14 Derivados de oxazol

Country Status (38)

Country Link
US (1) US6642389B2 (es)
EP (1) EP1392295B1 (es)
JP (2) JP4330883B2 (es)
KR (1) KR100654516B1 (es)
CN (1) CN100356917C (es)
AR (1) AR035892A1 (es)
AT (1) ATE327753T1 (es)
AU (1) AU2002342244B2 (es)
BG (1) BG66316B1 (es)
BR (1) BRPI0209821B1 (es)
CA (1) CA2445145C (es)
CY (1) CY1105160T1 (es)
CZ (1) CZ20033037A3 (es)
DE (1) DE60211891T2 (es)
DK (1) DK1392295T3 (es)
EC (1) ECSP034848A (es)
EG (1) EG25755A (es)
ES (1) ES2264482T3 (es)
GT (1) GT200200085A (es)
HR (1) HRP20030889B1 (es)
HU (1) HU230224B1 (es)
IL (2) IL158589A0 (es)
JO (1) JO2282B1 (es)
MA (1) MA27025A1 (es)
ME (1) ME01310B (es)
MX (1) MXPA03010435A (es)
MY (1) MY136761A (es)
NO (1) NO333833B1 (es)
NZ (1) NZ529033A (es)
PA (1) PA8544901A1 (es)
PE (1) PE20021152A1 (es)
PL (1) PL208074B1 (es)
PT (1) PT1392295E (es)
RU (1) RU2278859C2 (es)
SI (1) SI1392295T1 (es)
SK (1) SK287842B6 (es)
WO (1) WO2002092084A1 (es)
ZA (1) ZA200308538B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
HUP0302397A3 (en) * 2000-05-26 2007-02-28 Nippon Shinyaku Co Ltd Heterocyclic compounds and pharmaceutical compositions containing them
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
AU2002342244B2 (en) * 2001-05-15 2005-06-16 F. Hoffmann-La Roche Ag Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
CA2462200A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
ES2316736T3 (es) 2002-02-25 2009-04-16 Eli Lilly And Company Moduladores de receptores activados por proliferador de peroxisoma.
ES2350340T3 (es) * 2002-08-30 2011-01-21 F. Hoffmann-La Roche Ag Nuevos compuestos de 2-aril-tiazol como agonistas de pparalfa y ppargamma.
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
ES2319184T3 (es) * 2002-11-15 2009-05-05 Cadila Healthcare Limited Derivados de aralquil sustituidos.
ATE405560T1 (de) 2002-11-25 2008-09-15 Hoffmann La Roche Indolderivaten
US7268157B2 (en) * 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
FR2849849B1 (fr) * 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
CN1875002B (zh) * 2003-11-05 2011-08-03 霍夫曼-拉罗奇有限公司 作为ppar激动剂的苯基衍生物
EP1682507A1 (en) * 2003-11-05 2006-07-26 F. Hoffmann-La Roche Ag Benzannelated compounds as ppar activators
WO2005056536A1 (en) * 2003-12-10 2005-06-23 Ranbaxy Laboratories Limited Antidiabetic agents which exhibit activity against ppar
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
JP4682192B2 (ja) 2004-05-03 2011-05-11 エフ．ホフマン−ラ ロシュ アーゲー 肝ｘ受容体モジュレータとしてのインドリル誘導体
CN100436430C (zh) * 2004-05-24 2008-11-26 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物
CN100344618C (zh) * 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
WO2006108491A1 (en) * 2005-04-11 2006-10-19 Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg Improved process for preparing oxazole nitriles
US20060241073A1 (en) * 2005-04-20 2006-10-26 Wanders Ronaldus J A Means and methods for counteracting fatty acid accumulation
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
KR100847780B1 (ko) * 2006-10-26 2008-07-23 재단법인서울대학교산학협력재단 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제
US20100063041A1 (en) * 2007-03-07 2010-03-11 Ho-Sang Moon Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
EP2100604B1 (en) * 2008-03-10 2012-07-04 Nestec S.A. Medium chain dicarboxylic acids and their derivates and metabolic disorders
AU2009246626A1 (en) * 2008-05-15 2009-11-19 Merck Sharp & Dohme Corp. Oxazolobenzimidazole derivatives
CN102265280A (zh) 2008-12-23 2011-11-30 霍夫曼-拉罗奇有限公司 用于在收集设备上运行的结构化收集过程的实现、执行、数据收集和数据分析的管理方法和系统
PE20120421A1 (es) * 2009-01-23 2012-05-04 Hoffmann La Roche Composicion farmaceutica que comprende aleglitazar
CN101805337B (zh) * 2009-02-13 2012-05-23 天津药物研究院 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途
US8450496B2 (en) 2009-03-24 2013-05-28 Hoffman-La Roche Inc. Process for the preparation of propionic acid derivatives
ES2552310T3 (es) 2009-12-07 2015-11-27 F. Hoffmann-La Roche Ag Proceso para la obtención de derivados de ácido propiónico
CN102351852B (zh) * 2011-08-23 2014-06-18 上海交通大学 苯并呋喃类化合物及其制备方法、用途
WO2013181384A1 (en) 2012-05-31 2013-12-05 Ratiopharm Gmbh Solid state forms of aleglitazar sodium
MX2015002095A (es) 2012-09-12 2015-05-11 Hoffmann La Roche Formas solidas de acido (s)-2-metoxi-3-{4-[2-(5-metil-2-fenil-oxaz ol-4-il)-etoxi]benzo[b]tiofen-7-il}propionico y de sales del mismo.
EP3402482A1 (en) 2015-11-18 2018-11-21 H. Hoffnabb-La Roche Ag Aleglitazar for the treatment of diabetic kidney disease
WO2018002215A1 (en) 2016-06-30 2018-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cardiomyopathies
WO2020156683A1 (en) 2019-02-01 2020-08-06 F. Hoffmann-La Roche Ag Aleglitazar for use in the treatment or prevention of major adverse cardiac events
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
CA3227149A1 (en) * 2021-08-13 2023-02-16 Alebund Pharmaceuticals (Hong Kong) Limited Deuterated compounds
EP4615433A1 (en) 2022-11-08 2025-09-17 Genfit Ppar-alpha/gamma agonist for use in the treatment of liver failure
CN118480034B (zh) * 2023-02-13 2025-02-11 礼邦医药(香港)有限公司 氘代化合物的晶型或盐

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011326A (en) 1975-07-29 1977-03-08 Merck & Co., Inc. 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
RU2032677C1 (ru) * 1992-05-05 1995-04-10 Бристоль-Мейерз Сквибб Компани Производные оксазола
CA2139442A1 (en) 1992-07-03 1994-01-20 David Haigh Heterocyclic compounds as pharmaceutical
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
PT1027043E (pt) 1996-12-10 2005-02-28 Bristol Myers Squibb Co Benzodioxole benzofurano di-hidrobenzofurano e benzodioxano como agentes melatonergicos
DE19711616A1 (de) * 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6121397A (en) 1997-07-14 2000-09-19 Xerox Corporation Polymerization processes using oligomeric compound, monomer and surfactant
HN1998000118A (es) 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
EP0903343B1 (en) 1997-09-19 2003-05-28 SSP Co., Ltd. Alpha-Substituted phenylpropionic acid derivative and medicine containing the same
ATE286032T1 (de) 1998-04-23 2005-01-15 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
EP1078923B1 (en) 1999-08-02 2006-03-08 F. Hoffmann-La Roche Ag Process for the preparation of benzothiophene derivatives
HUP0300857A3 (en) * 2000-08-23 2007-03-28 Lilly Co Eli Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
AU2002342244B2 (en) * 2001-05-15 2005-06-16 F. Hoffmann-La Roche Ag Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes

Also Published As

Publication number Publication date
IL158589A (en) 2010-11-30
CN1509173A (zh) 2004-06-30
HUP0400992A2 (hu) 2004-08-30
SI1392295T1 (sl) 2006-10-31
MY136761A (en) 2008-11-28
EP1392295A1 (en) 2004-03-03
NO333833B1 (no) 2013-09-30
BG66316B1 (bg) 2013-04-30
JP2009138011A (ja) 2009-06-25
CA2445145C (en) 2008-10-14
RU2003134150A (ru) 2005-06-10
EG25755A (en) 2012-06-26
CZ20033037A3 (cs) 2004-06-16
KR100654516B1 (ko) 2006-12-05
HK1067534A1 (en) 2005-04-15
CN100356917C (zh) 2007-12-26
BRPI0209821B1 (pt) 2016-09-27
NO20035086L (no) 2003-11-14
SK13852003A3 (en) 2004-10-05
HRP20030889B1 (hr) 2011-10-31
EP1392295B1 (en) 2006-05-31
JP2004529174A (ja) 2004-09-24
PL367087A1 (en) 2005-02-21
RU2278859C2 (ru) 2006-06-27
ATE327753T1 (de) 2006-06-15
IL158589A0 (en) 2004-05-12
BR0209821A (pt) 2004-06-01
PA8544901A1 (es) 2003-01-24
ECSP034848A (es) 2003-12-24
DK1392295T3 (da) 2006-10-02
ES2264482T3 (es) 2007-01-01
JP4330883B2 (ja) 2009-09-16
CA2445145A1 (en) 2002-11-21
NZ529033A (en) 2005-06-24
WO2002092084A1 (en) 2002-11-21
MXPA03010435A (es) 2004-03-09
HU230224B1 (hu) 2015-10-28
KR20030096397A (ko) 2003-12-24
HUP0400992A3 (en) 2007-11-28
US6642389B2 (en) 2003-11-04
BG108362A (bg) 2005-03-31
PT1392295E (pt) 2006-09-29
PL208074B1 (pl) 2011-03-31
CY1105160T1 (el) 2009-11-04
SK287842B6 (sk) 2011-12-05
US20030055265A1 (en) 2003-03-20
AU2002342244B2 (en) 2005-06-16
PE20021152A1 (es) 2003-02-07
NO20035086D0 (no) 2003-11-14
AR035892A1 (es) 2004-07-21
DE60211891T2 (de) 2007-05-24
ZA200308538B (en) 2005-04-26
HRP20030889A2 (en) 2005-08-31
ME01310B (me) 2011-10-10
JO2282B1 (en) 2005-09-12
DE60211891D1 (de) 2006-07-06
MA27025A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
GT200200085A (es) Derivados de oxazol
GT200300268A (es) Nuevos derivados fluoroglucosidos heterociclicos, medicamentos que contienen estos compuestos y el uso de los mismos
GT200300038A (es) Nuevos derivados de piridina y quinolina
GT200100146A (es) Activadores de glucoquinasa acetamida benzenica sustituida con atomos de alfa-acilo y alfa-heteroatomo.
GT200300096A (es) Activadores de cicloalquil sustituidos y cicloalquil oxigenados de glucoquinasa
GT200600430A (es) Compuestos de carboxiamina y metodos de uso de los mismos
PA8562801A1 (es) Nuevos derivados de pirido (2,1-a) isoquinolina
GT200300292A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
GT200300015A (es) Aza-arilpiperazinas
GT200600342A (es) Compuestos de cicloalquilo amino-hidantoina y uso de estos para la modulacion de beta-secretasa
GT200400092A (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
GT200300269A (es) Nuevos derivados fluoroglucosidos aromaticos, medicamentos que contienen estos compuestos y sus usos
PA8592001A1 (es) Activadores de glocoquinasa heteroaromaticos de seis miembros 5-sustituidos
GT200600136A (es) Heteroarilamidas [3.1.0] biciclicas como inhibidores del transporte de glicina de tipo i
GT200400161A (es) Piridinonas sustituidas
GT200400146A (es) Derivados sustituidos del dioxido de tiazol-benzoisotiazol, procedimiento para su preparacion y su uso
GT200200191A (es) Derivados de 1,6-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
DE602005026306D1 (de) Carbazolderivat und davon gebrauch machende organische lichtemittierende vorrichtung
GT200600428A (es) Compuestos organicos
GT200200220AA (es) Nuevos derivados de pirrolidina
GT200300072AA (es) Aminoacidos con afinidad por la proteina alfa2delta (solicitud fraccionaria
PA8616801A1 (es) Compuestos de pirazolilo e imidazolilo biciclicos y uso de los mismos
AR043783A1 (es) Difenilazetidinona con propiedades fisiologicas, medicamentos que comprenden este compuesto y su uso
GT200500238A (es) Fenilaminotiazoles sustituidos y su uso
GT200300046A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso